Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


04.08.2025

1 Am J Pathol
2 Ann Thorac Surg
2 Arch Pathol Lab Med
4 BMC Cancer
1 Br J Cancer
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
2 Cancer Res
1 Carcinogenesis
1 Chest
4 Clin Lung Cancer
2 Clin Nucl Med
1 Eur J Cancer
1 Eur J Cardiothorac Surg
1 J Cancer Res Clin Oncol
1 J Natl Cancer Inst
2 J Thorac Cardiovasc Surg
2 Lung Cancer
1 Oncogene
1 Oncol Rep
1 PLoS Med
4 PLoS One
1 Proc Natl Acad Sci U S A
1 Thorax


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Pathol

  1. MOSKAL A, Myrczek R, Wawro M, Auladell LR, et al
    Autocrine Transforming Growth Factor-beta Signaling Promotes Cell Motility and Chemokine Secretion in an Angiomyolipoma-Derived Cell Model of Lymphangioleiomyomatosis.
    Am J Pathol. 2025;195:1394-1410.
    PubMed         Abstract available


    Ann Thorac Surg

  2. NG AP, Sanaiha Y, Hadaya JE, Verma A, et al
    Risk of Financial Toxicity Among Adults Undergoing Lung and Esophageal Resections for Cancer.
    Ann Thorac Surg. 2025;120:283-292.
    PubMed         Abstract available

  3. RICE D, Singhal S, Niemeyer E, Sarkaria I, et al
    Intraoperative Molecular Imaging with Pafolacianine in Resection of Occult Pulmonary Malignancy in the ELUCIDATE trial.
    Ann Thorac Surg. 2024 Oct 21:S0003-4975(24)00869.
    PubMed         Abstract available


    Arch Pathol Lab Med

  4. SABATINI P, Ta R, Peralta M, Anderson M, et al
    Tissue Prior to the Initial Hematoxylin-Eosin Section Demonstrates Value as an Alternative Source of DNA for Molecular Testing.
    Arch Pathol Lab Med. 2025;149:761-768.
    PubMed         Abstract available

  5. BOUANZOUL MA, Rosen Y
    Lymphangioleiomyomatosis: A Review.
    Arch Pathol Lab Med. 2025;149:775-788.
    PubMed         Abstract available


    BMC Cancer

  6. LI F, Li F, Lu H, Zhao D, et al
    Analysis of age-related survival differences in advanced non-small cell lung cancer patients based on real-world data.
    BMC Cancer. 2025;25:1244.
    PubMed         Abstract available

  7. OLAYODE OO, Ogunoye BT, Oladeji EO, Olayinka OE, et al
    Cerebrospinal fluid Circulating Tumor DNA (ctDNA) as a biomarker for CNS metastases in Non-Small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis comparing CSF ctDNA and traditional methods.
    BMC Cancer. 2025;25:1246.
    PubMed         Abstract available

  8. KO MM, Na SW, Yi JM, Jang H, et al
    Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study.
    BMC Cancer. 2025;25:1229.
    PubMed         Abstract available

  9. CHEN Z, Tang C, Ma X, Tian P, et al
    Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China.
    BMC Cancer. 2025;25:1216.
    PubMed         Abstract available


    Br J Cancer

  10. SHIMAUCHI A, Iwama E, Ibusuki R, Tsutsumi H, et al
    Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.
    Br J Cancer. 2025 Jul 28. doi: 10.1038/s41416-025-03126.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  11. XU T, Dillon JS, Quelle DE, Nash SH, et al
    Risk Factors Associated with Gastroenteropancreatic and Lung Neuroendocrine Tumors: A Nested Case-Control Study from the All of Us Research Program.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1395-1404.
    PubMed         Abstract available


    Cancer Lett

  12. ZADRA I, Abad E, Krasko A, Porqueras VC, et al
    A novel mismatch repair deficient lung adenocarcinoma model for immunotherapy research.
    Cancer Lett. 2025;629:217882.
    PubMed         Abstract available


    Cancer Res

  13. QIN N, Wang Z, Xu X, Xie Y, et al
    Comprehensive Characterization of Somatic Mutation Timing Reveals the Evolutionary Trajectory of Lung Adenocarcinoma in Chinese Patients.
    Cancer Res. 2025;85:2905-2920.
    PubMed         Abstract available

  14. REDIN E, Otegui N, Santos M, Leon S, et al
    Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy.
    Cancer Res. 2025 Jul 25. doi: 10.1158/0008-5472.CAN-24-2772.
    PubMed         Abstract available


    Carcinogenesis

  15. DONG M, Thakral A, Byrne KS, Bosse Y, et al
    Genome-wide association study of early-stage non-small cell lung cancer prognosis: a pooled analysis in the International Lung Cancer Consortium.
    Carcinogenesis. 2025 Aug 1:bgaf031. doi: 10.1093.
    PubMed         Abstract available


    Chest

  16. SERNA-BLASCO R, Medina K, Sala MA, Aguiar D, et al
    KRAS Mutation Status in Non-Small Cell Lung Cancer: Distribution Across Occupational Categories.
    Chest. 2025 Jul 15:S0012-3692(25)00832-3. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available


    Clin Lung Cancer

  17. ATLAGH L, Toublanc AC, Roch B, Marinello A, et al
    Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study.
    Clin Lung Cancer. 2025 Jun 25:S1525-7304(25)00134.
    PubMed         Abstract available

  18. LOCKE M, Aung WY, Esposito M, Seetharamu N, et al
    Lymphovascular Invasion is a Predictor of Postoperative Recurrence or Death in Stage I Non-small-cell Lung Cancer (NSCLC).
    Clin Lung Cancer. 2025 Jul 3:S1525-7304(25)00145.
    PubMed         Abstract available

  19. SHARP J, Young P, Zhao S, Wei L, et al
    Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2025 Jul 5:S1525-7304(25)00146.
    PubMed        

  20. MORGILLO F, Del Signore E, Bria E, de Marinis F, et al
    The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.
    Clin Lung Cancer. 2025 Jul 9:S1525-7304(25)00147.
    PubMed         Abstract available


    Clin Nucl Med

  21. DUARTE PS, Moraes RDR, Costa EAD, Sapienza MT, et al
    Sessile Serrated Adenoma Plus Lipoid Pneumonia Mimicking a Colon Cancer With Pulmonary Metastatic Lesions on 18F-FDG PET/CT.
    Clin Nucl Med. 2025 Jun 6. doi: 10.1097/RLU.0000000000005744.
    PubMed         Abstract available

  22. GILLON P, Schwartz P, Yaouanq M, Godbert Y, et al
    Complete Radiologic Response After 177Lu-DOTATATE Therapy in Treatment of a Lung Metastatic Intracranial Atypical Meningioma.
    Clin Nucl Med. 2025;50:e572-e574.
    PubMed         Abstract available


    Eur J Cancer

  23. ALEXANDER M, Cheng Y, Lee SH, Passaro A, et al
    Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
    Eur J Cancer. 2025;227:115624.
    PubMed         Abstract available


    Eur J Cardiothorac Surg

  24. CLAES E, Verleden SE, De Raedemaecker J, Annaert P, et al
    Selective Pulmonary Artery Perfusion with Blood Flow Occlusion as a Treatment for Lung Malignancies.
    Eur J Cardiothorac Surg. 2025;67:ezaf235.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  25. MANGUES-BAFALLUY I, Bernardez B, Martinez-Sesmero JM, Navarro-Ruiz A, et al
    Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study.
    J Cancer Res Clin Oncol. 2025;151:224.
    PubMed        


    J Natl Cancer Inst


  26. Correction to: Obesity-Specific Improvement of Lung Cancer Outcomes and Immunotherapy Efficacy with Metformin.
    J Natl Cancer Inst. 2025 Jul 28:djaf184. doi: 10.1093.
    PubMed        


    J Thorac Cardiovasc Surg

  27. KNEUERTZ PJ, Villamizar N, Altorki NK, Phillips JD, et al
    Minimally Invasive Resection of Non-small Cell Lung Cancer after Chemoimmunotherapy - A Multicenter Study in Academic Hospitals.
    J Thorac Cardiovasc Surg. 2025 Jul 25:S0022-5223(25)00637.
    PubMed         Abstract available

  28. MARTIN LW
    Towards a Chemotherapy-Free Future: Adjuvant Alectinib in Early Stage Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2025 Jul 29:S0022-5223(25)00580.
    PubMed        


    Lung Cancer

  29. REGUART N, Sampietro-Colom L, Juan-Vidal O, Aguilo M, et al
    Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study).
    Lung Cancer. 2025;206:108677.
    PubMed         Abstract available

  30. XENOPHONTOS E, Giaj Levra N, Durieux V, van Geffen WH, et al
    Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group.
    Lung Cancer. 2025;207:108671.
    PubMed         Abstract available


    Oncogene

  31. CAO K, Wei S, Ma T, Zou X, et al
    RFX2-BNIP3 axis-driven adaptive mitophagy promotes resistance to ACK1-targeted therapy in non-small cell lung cancer.
    Oncogene. 2025 Jul 25. doi: 10.1038/s41388-025-03502.
    PubMed         Abstract available


    Oncol Rep

  32. LIN Z, Chen Q, Chen Z, Peng T, et al
    Advances in the chemo?preventive effects and mechanisms of ursolic acid against lung cancer (Review).
    Oncol Rep. 2025;54:126.
    PubMed         Abstract available


    PLoS Med

  33. CHEN H, Yu L, Liang F, Zhou Y, et al
    Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China.
    PLoS Med. 2025;22:e1004680.
    PubMed         Abstract available


    PLoS One

  34. CENGIZ MA, Senel T, Kara M
    Bayesian robust symmetric regression for medical data with heavy-tailed errors and censoring.
    PLoS One. 2025;20:e0329589.
    PubMed         Abstract available

  35. ZHANG X, Liu J, Zhao Z, Jiang J, et al
    Effects of long-term metformin intake on postoperative clinicopathological characteristics in patients with invasive lung adenocarcinoma and type 2 diabetes mellitus: A retrospective analysis.
    PLoS One. 2025;20:e0329277.
    PubMed         Abstract available

  36. SENNA KM, Zimmermann IR, Costa MGSD, Tura BR, et al
    Cost-effectiveness assessment of liquid biopsy for early detection of lung cancer in Brazil.
    PLoS One. 2025;20:e0328631.
    PubMed         Abstract available

  37. HARDI H, Fitrianti Z, Utama KE, Vidya AP, et al
    Tailoring oral targeted therapies dosage in lung cancer: A systematic review of pharmacokinetics studies on renal and hepatic impairment.
    PLoS One. 2025;20:e0324056.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  38. MASO L, Rajak E, Hattori T, Hu Z, et al
    Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib.
    Proc Natl Acad Sci U S A. 2025;122:e2509012122.
    PubMed         Abstract available


    Thorax

  39. WANG K, Zhao J, Yang D, Sun M, et al
    Association between ultra-processed food consumption and lung cancer risk: a population-based cohort study.
    Thorax. 2025 Jul 29:thorax-2024-222100. doi: 10.1136/thorax-2024-222100.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.